Brustin & Lundblad, Ltd. Is Proud To Announce Their Jury Verdict Victory
CHICAGO, Sept. 25, 2018 /PRNewswire/ -- BRUSTIN & LUNDBLAD, LTD. won a jury verdict in the amount of $18,500,000.00 on behalf of a 12-year old boy who was injured by the prescription of a mental health drug to his mother when he was in the fetal stage. In addition, it was alleged that the monitoring of the drug was improper. There was an additional allegation that the quantity used was inappropriate. The child sustained both physical spine damage and brain damage, and impairment intellectually.
The jury deliberated for 5 hours, returning a verdict which was contrary to the protestations of Northwestern Hospital and their prior offer of $1,500,000.00 at the start of trial.
This case had been pending for approximately ten years. It was suggested that, had the minor victim been able to receive some supplemental tutoring and additional physical and occupational therapy promptly, he may have improved intellectually so as to prevent his not being able to read and write. The child's condition continues to require catheterization and medical monitoring, with normal life expectancy if he receives adequate and expert care.
The case was tried by Marvin Brustin and Milo Lundblad of Brustin & Lundblad, Ltd. Caption of the matter is Charles Muhammad, et al. v.Northwestern Memorial Hospital, et al., Court No. 12 L 12174 (Cook County, Daley Center).
Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...
Vaccines Market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0% from 2024 to 2029 according to a new report by MarketsandMarketstm. Similarly, the vaccines...
Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced that updated Phase 1/2 data for AU-007 will be presented at the American Society...
A monument park and website honoring medical frontline and essential workers worldwide who risked their lives during the COVID-19 pandemic will break ground this summer in Chicago, Illinois. The COVID-19 Monument of Honor, Remembrance, and Resilience...
Precigen, Inc. , a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase 2 study of PRGN-2012 AdenoVerse immunotherapy...
The two poster presentations will report -first combination data from the Phase 1/2a study with BI-1808 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as an update on monotherapy armcombination data from the...
